Data gathered: November 27
Alternative Data for Kyverna Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 21 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 60 | Sign up | Sign up | Sign up |
| Google Trends | 20 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 343 | Sign up | Sign up | Sign up |
| Twitter Followers | 362 | Sign up | Sign up | Sign up |
| Twitter Mentions | 28 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 47 | Sign up | Sign up | Sign up |
| Linkedin Employees | 135 | Sign up | Sign up | Sign up |
About Kyverna Therapeutics
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.
| Price | $5.43 |
| Target Price | Sign up |
| Volume | 306,720 |
| Market Cap | $285M |
| Year Range | $3.99 - $26.9 |
| Dividend Yield | 0% |
| Analyst Rating | 86% buy |
| Industry | Biotechnology |
In the news
 |
Kyverna Therapeutics (NASDAQ:KYTX) Price Target Lowered to $24.00 at Wells Fargo & CompanyNovember 18 - ETF Daily News |
 |
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% dropNovember 16 - Yahoo |
 |
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024November 13 - Yahoo |
|
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13 - Yahoo |
 |
Reviewing Kyverna Therapeutics (NASDAQ:KYTX) & Turnstone Biologics (NASDAQ:TSBX)November 6 - ETF Daily News |
 |
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of “Buy” by BrokeragesNovember 5 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 0 | 0 | -34M | -34M | -0.799 |
| Q2 '24 | 0 | 530,000 | -530,000 | -29M | -28M | -0.670 |
| Q1 '24 | 0 | 480,000 | -480,000 | -27M | -26M | -1.120 |
| Q4 '23 | 0 | 460,000 | -460,000 | -21M | -20M | -26.860 |
| Q3 '23 | 0 | 440,000 | -440,000 | -15M | -16M |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Kyverna Therapeutics (KYTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Kyverna Therapeutics?
The Market Cap of Kyverna Therapeutics is $285M.
What is the current stock price of Kyverna Therapeutics?
Currently, the price of one share of Kyverna Therapeutics stock is $5.43.
How can I analyze the KYTX stock price chart for investment decisions?
The KYTX stock price chart above provides a comprehensive visual representation of Kyverna Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kyverna Therapeutics shares. Our platform offers an up-to-date KYTX stock price chart, along with technical data analysis and alternative data insights.
Does KYTX offer dividends to its shareholders?
As of our latest update, Kyverna Therapeutics (KYTX) does not offer dividends to its shareholders. Investors interested in Kyverna Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Kyverna Therapeutics?
Some of the similar stocks of Kyverna Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.